Across TCGA pan-cancer cohorts, NPIPB9 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated NPIPB9 data layer compared with 1 for mutation status.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher NPIPB9 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated NPIPB9 expression acts as an unfavorable survival marker, although some lineages such as CESC and LGG show a favorable association.
KIRC, ACC, and COAD are the cancer types where NPIPB9 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.